OUT ONE !!!!
Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.
AstraZeneca will no longer play in the neuroscience space, company executives said in an investor call on Tuesday, presenting the pharma’s first-quarter 2025 earnings report.
“There’s a lot of things we can’t fund and we cannot be everywhere,” CEO Pascal Soriot said during the call. “CNS really is probably better managed by other companies that have a focus on that.”
https://www.biospace.com/business/a...uroscience-prioritizes-weight-loss-immunology
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.99 |
Change
0.135(1.05%) |
Mkt cap ! $1.617B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.85 | $6.981M | 533.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 891 | $12.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.99 | 366 | 7 |
View Market Depth
| Last trade - 15.52pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |